Monday, June 27, 2016 9:18:18 AM
One risk for NNVC from a declining stock price is removal from the New York/AMEX Small cap board. With market Cap now below 100 million a decline in price below 1.00 could trigger a review by the listing committee and being put on a watch-list.
It's been sometime since I worked on the AMEX floor - this was prior to the merger with the NYSE to form the small cap board. So the rules may have changed. There was a listing committee charged with the job of determining if candidates wanting listing met the criteria for initial listing. This minimum price requirement was the reason for the reverse split ( 1 for 3.5) undertaken by NNVC several years ago.
The requirements for getting listed are more stringent than for remaining listed, but there are indeed requirements to remain listed.
You can check them out here
http://venturelawcorp.com/nyse-mkt-listing-requirements/
When a stock loses its listing it means banishment to the pink-sheets. That changes a lot for a company and not in a good way. I believe NNVC understands this and will do everything they can to prevent it - even if it means buying by insiders.
New capital raises by a pink-sheet company are next to impossible on reasonable terms.
Trendliner
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM